Cumberland Pharmaceuticals Inc.

NasdaqGS:CPIX Stock Report

Market Cap: US$22.5m

Cumberland Pharmaceuticals Management

Management criteria checks 3/4

Cumberland Pharmaceuticals' CEO is A. Kazimi, appointed in Jan 1999, has a tenure of 25.33 years. total yearly compensation is $1.17M, comprised of 57.7% salary and 42.3% bonuses, including company stock and options. directly owns 40.18% of the company’s shares, worth $9.06M. The average tenure of the management team and the board of directors is 6.4 years and 11 years respectively.

Key information

A. Kazimi

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage57.7%
CEO tenure25.3yrs
CEO ownership40.2%
Management average tenure6.4yrs
Board average tenure11yrs

Recent management updates

Recent updates

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Mar 07
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

Jan 09
Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Oct 02
Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Aug 10
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Mar 18
Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Nov 02
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Jul 20
Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Apr 15
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Checking In On Cumberland Pharmaceuticals

Jan 04

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Nov 09
Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Apr 21
We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

Feb 13
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Nov 19
One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

CEO Compensation Analysis

How has A. Kazimi's remuneration changed compared to Cumberland Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$1mUS$675k

-US$6m

Sep 30 2023n/an/a

-US$2m

Jun 30 2023n/an/a

-US$2m

Mar 31 2023n/an/a

-US$4m

Dec 31 2022US$1mUS$635k

-US$6m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$9m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$1mUS$610k

-US$6m

Sep 30 2021n/an/a

-US$3m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$1mUS$590k

-US$7m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$1mUS$567k

-US$9m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$1mUS$545k

-US$11m

Sep 30 2018n/an/a

-US$6m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

-US$9m

Dec 31 2017US$1mUS$523k

-US$8m

Compensation vs Market: A.'s total compensation ($USD1.17M) is above average for companies of similar size in the US market ($USD664.85K).

Compensation vs Earnings: A.'s compensation has been consistent with company performance over the past year.


CEO

A. Kazimi (65 yo)

25.3yrs

Tenure

US$1,169,530

Compensation

Mr. A. J. Kazimi, MBA, founded Cumberland Pharmaceuticals Inc. in 1999 and has been its Chairman and Chief Executive Officer since 1999. Mr. Kazimi serves as the President of Cumberland Pharmaceuticals Inc...


Leadership Team

NamePositionTenureCompensationOwnership
A. Kazimi
Founder25.3yrsUS$1.17m40.18%
$ 9.1m
John Hamm
VP & CFO3yrsUS$282.32k0.18%
$ 41.3k
James Herman
Executive VP of National Accounts & Chief Compliance Officer7.6yrsUS$400.15k0.27%
$ 60.8k
Chris Bitterman
Vice President of Sales & Marketingno dataUS$316.29k0.033%
$ 7.4k
Todd Anthony
Vice President of Organizational Developmentno dataUS$330.85k0.12%
$ 26.0k
Jean Marstiller
Senior VP of Administrative Services & Corporate Secretaryno dataUS$298.01kno data
Adam Mostafa
Managing Director5.3yrsno datano data
Erin Gull
Senior Corporate Relations Associateno datano datano data

6.4yrs

Average Tenure

65yo

Average Age

Experienced Management: CPIX's management team is seasoned and experienced (6.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
A. Kazimi
Founder25.3yrsUS$1.17m40.18%
$ 9.1m
Joseph Williams
Member of Pharmaceutical Advisory Boardno datano datano data
Joseph Galante
Independent Director5.7yrsUS$61.20k0.42%
$ 94.4k
Robert Roberts
Member of Medical Advisory Boardno datano datano data
Gordon Bernard
Chairman of Medical Advisory Board & Independent Director14.3yrsUS$98.00kno data
J. Hix
Member of Pharmaceutical Advisory Boardno dataUS$233.65kno data
Martin Brown
Director1.8yrsUS$50.00k0.042%
$ 9.5k
David Warrell
Member of Medical Advisory Boardno datano datano data
Timothy Meakin
Member of Pharmaceutical Advisory Boardno datano datano data
Ben deBoisblanc
Member of Medical Advisory Boardno datano datano data
Caroline Young
Independent Director7.7yrsUS$61.20k0.19%
$ 42.5k
James Jones
Independent Director14.3yrsUS$60.20kno data

11.0yrs

Average Tenure

71yo

Average Age

Experienced Board: CPIX's board of directors are seasoned and experienced ( 11 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.